STOCK TITAN

Bio-Techne Corporation - $TECH STOCK NEWS

Welcome to our dedicated page for Bio-Techne Corporation news (Ticker: $TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Techne Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Techne Corporation's position in the market.

Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has filed a patent infringement lawsuit against Molecular Instruments, Inc. in Europe to protect its patented RNAscope® ISH technology. The lawsuit alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439. Bio-Techne aims to halt the infringement, seek damages, and obtain injunctive relief in key European markets to defend its position as a global leader in spatial biology research and clinical applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) will host a conference call on May 1, 2024, to review third quarter fiscal 2024 financial results. Bio-Techne is a leading developer of high-quality purified proteins, reagent solutions, and diagnostic products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences earnings
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announces that Advanced Cell Diagnostics (ACD) has reached a milestone of over 10,000 peer-reviewed publications utilizing RNAscope™ ISH technology, solidifying its leadership in spatial biology applications. The increasing global customer awareness and market adoption signify ACD's significant impact in enabling ground-breaking biologic discoveries and therapeutic advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
Rhea-AI Summary
Bio-Techne (TECH) will present its cancer research solutions at the AACR annual meeting in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne (TECH) wins prestigious awards for its R&D Systems and Advanced Cell Diagnostics brands. The company received the 'ELISA Kit Supplier of the Year' award for its R&D Systems brand and 'The Innovation Award' for Advanced Cell Diagnostics. These accolades highlight Bio-Techne's commitment to scientific excellence and innovation in the research and clinical diagnostic communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announces a partnership between Lunaphore and Nikon to expand access to spatial biology services in the US. The collaboration aims to provide cutting-edge technology for researchers and clinicians to enhance spatial biology research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
partnership
Rhea-AI Summary
Bio-Techne's QuantideX qPCR BCR-ABL IS Kit is now compliant with the latest EU diagnostic regulations, enhancing monitoring for CML patients. The kit offers robust quantification of BCR-ABL1 and ABL1 transcripts, aiding in TKI therapy response assessment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) will have its President, Will Geist, present at the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. The presentation will be available via a live webcast on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation (TECH) President and CEO to present at Barclays Global Healthcare Conference. Live webcast available on Bio-Techne's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) reported second-quarter financial results, showing a 2% organic revenue decline to $272.6 million, with GAAP EPS at $0.17 and adjusted EPS at $0.40. The company experienced growth in instrument consumables and academic end markets, but saw a decrease in operating income and margin. The Diagnostics and Genomics segment saw a 11% increase in net sales, but a decrease in operating margin due to the Lunaphore acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
Bio-Techne Corporation

Nasdaq:TECH

TECH Rankings

TECH Stock Data

12.67B
155.39M
0.97%
100.54%
3.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
MINNEAPOLIS

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.